The Swiss group shells out $2bn for Synnovation’s mutation-selective PI3Kα inhibitor.
ApexOnco Front Page
Recent articles
A unique VEGF trispecific and mRNA-based T-cell engager will also be featured at the congress.
Of 15 treatment-emergent adverse events, only one was deemed related to therapy.
Cross-licensing pact brings in SKB105, and hands off China rights to CR-001 before first-in-human studies.
Relapsed data are uncompetitive, but the front-line PACC-mutant space offers hope.
With a phase 3 trial of the trispecific T-cell engager ramantamig, J&J will challenge itself.
The upcoming Rasolute-304 trial will compare daraxonrasib versus observation.
Deteriorating efficacy and a treatment-related death with Zynlonta plus Columvi spook investors.
